(Q45099109)

English

Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States

scientific article published on 19 November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

9 December 2017

Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States (English)

1 reference

Europe PubMed Central

9 December 2017

type 2 diabetes

0 references

United States of America

0 references

author name string

Stephen S Johnston

1

1 reference

Europe PubMed Central

9 December 2017

Hiep Nguyen

2

1 reference

Europe PubMed Central

9 December 2017

Eugene Felber

3

1 reference

Europe PubMed Central

9 December 2017

Katherine Cappell

4

1 reference

Europe PubMed Central

9 December 2017

James K Nelson

5

1 reference

Europe PubMed Central

9 December 2017

Bong-Chul Chu

6

1 reference

Europe PubMed Central

9 December 2017

Iftekhar Kalsekar

7

1 reference

Europe PubMed Central

9 December 2017

language of work or name

0 references

publication date

19 November 2014

1 reference

Europe PubMed Central

9 December 2017

Advances in Therapy

1 reference

Europe PubMed Central

9 December 2017

31

1 reference

Europe PubMed Central

9 December 2017

11

1 reference

Europe PubMed Central

9 December 2017

1119-1133

1 reference

Europe PubMed Central

9 December 2017

https://scigraph.springernature.com/pub.10.1007/s12325-014-0166-0

0 references

Standards of medical care in diabetes--2013

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

AACE Comprehensive Diabetes Management Algorithm 2013. Endocrine Practice

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

A review of diabetes treatment adherence and the association with clinical and economic outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Costs of medication nonadherence in patients with diabetes mellitus: a systematic review and critical analysis of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Mail-order pharmacy use and medication adherence among Medicare Part D beneficiaries with diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

The impact of medication regimen factors on adherence to chronic treatment: a review of literature

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

A checklist for medication compliance and persistence studies using retrospective databases.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Good and poor adherence: optimal cut-point for adherence measures using administrative claims data

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Risking health to avoid injections: preferences of Canadians with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Predictors of medication adherence in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0166-0

21 January 2018

Identifiers

10.1007/S12325-014-0166-0

1 reference

Europe PubMed Central

9 December 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

9 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45099109&oldid=2065770711"